Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
13 Results for "
braf protac
" in MedChemExpress (MCE) Product Catalog:
Products (13)
13 Results for "braf protac" in MCE Product Catalog:
1
SJF-0628 is a PROTAC degrader of BRAF mutants, with a DC50 of 6.8 nM against BRAF V600E. SJF-0628 induces the ubiquitination and degradation of BRAF mutants in various cancer cell lines. SJF-0628 reduces pMEK and pErk levels. SJF-0628 exhibits antitumor activity. SJF-0628 can be used in research on colorectal cancer, melanoma, lung cancer, and triple-negative breast cancer .
PROTAC BRAF-V600E degrader-1 (compound 23) is a potent PROTAC BRAF-V600E degrader whlie no degradation activity against BRAF-WT. PROTAC BRAF-V600E degrader-1 exhibits Kd values of 2.4 nM and 2 nM for BRAF and BRAF-V600E, respectively. PROTAC BRAF-V600E degrader-1 degrades BRAF-V600E via the ubiquitin-proteasome system (UPS) and inhibits the growth of melanoma cells .
Cat. No.: HY-175726
CAS No.: 3094183-96-4
Research Areas:
BRAF ligand-Linker Conjugate 1 is a target protein ligand-linker conjugate that can be used to synthesize PROTAC CST905(HY-175435) .
Cat. No.: HY-130617
CAS No.: 2351106-38-0
Research Areas:
Pomalidomide-amido-C1-Br is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker. Pomalidomide-amido-C1-Br can be used to design a B-Raf PROTAC degrader PROTAC B-Raf degrader 1 (HY-111758). PROTAC B-Raf degrader 1 has anti-cancer activity .
Cat. No.: HY-137488
CAS No.: 2417296-82-1
PROTAC BRAF-V600E degrader-2 (compound 12) is a potent BRAF-V600E degrader with Kds of 14.4 nM and 9.5 nM for BRAF and BRAF-V600E, respectively. PROTAC BRAF-V600E degrader-2 selectively degraded the kinase domain of BRAF-V600E but not the wild-type BRAF. PROTAC BRAF-V600E degrader-2 inhibits melanoma cell growth .
Cat. No.: HY-W074340
CAS No.: 63984-03-2
Target:
Research Areas:
tert-Butyl 5-aminopentanoate is a PROTAC linker. tert-Butyl 5-aminopentanoate can be used to synthesize the PROTAC BRAF-V600E degrader-2 (HY-137488).
Cat. No.: HY-187012
CAS No.: 2882167-76-0
Research Areas:
BRAF ligand-2 is a BRAF ligand that can be used to synthesize PROTACs, such as Tagarafdeg (HY-153341) .
Cat. No.: HY-44237
CAS No.: 444289-11-6
Research Areas:
Pomalidomide-CO-C-NH2 (Compound 8) is a conjugate of an E3 ligand and a linker, which can be used for the synthesis of PROTACs, such as PROTAC B-Raf degrader 1 (HY-111758) .
Cat. No.: HY-184581
CAS No.: 2412056-33-6
Research Areas:
Pomalidomide-5-C4-acid is an E3 ligase ligand-linker conjugate that can be used for PROTAC synthesis, such as PROTAC BRAF-V600E degrader-2 (HY-137488) .
Cat. No.: HY-180329
CAS No.: 2417296-83-2
Target:
CG 858-Neg (compound 13) is a negative control for Thalidomide (HY-14658)-derived PROTAC degraders, targeting BRAF and BRAF V600E with Ki values of 9.5 nM and 14.4 nM, respectively. CG 858-Neg inhibits downstream ERK phosphorylation and suppresses BRAF V600E-driven melanoma (e.g., A375 cells, IC50=492 nM) and colorectal cancer (e.g., HT-29 cells, IC50=459 nM) cells. CG 858-Neg can be used in research related to melanoma and colorectal cancer .
Cat. No.: HY-184546
CAS No.: 2417296-80-9
Research Areas:
BRAFV600E ligand-1 is a BRAFV600E ligand. BRAFV600E ligand-1 can serve as a target protein ligand for the synthesis of BRAFV600E PROTAC degraders, such as PROTAC BRAF-V600E degrader-2 (HY-137488) .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
